Clinical trials: Anti-coagulation Therapy
Traumatic Intracranial Hemorrhage, Traumatic Brain Injury
No Cases of Delayed Intracranial Hemorrhage (d-ICH) Among Patients With Mild Traumatic Brain Injury (mTBI) on Oral Anticoagulation Therapy
Abstract Purpose Patients with anticoagulation therapy has a higher risk of developing traumatic Intracranial Hemorrhage (tICH).
- Trial name
- NCT05609734
- Testing
- no intervention, only observational retrospective study
- Where
- Sweden
- Volunteers
- 249 people
- Sponsor
- Umeå University
Portal Vein Thrombosis, Liver Cirrhosis
Portal Vein Thrombosis in Cirrhosis: Incidence, Outcomes and Anticoagulation
Portal vein thrombosis (PVT) is a blood-clot complication that occurs in some people with liver cirrhosis and can worsen bleeding, ascites, encephalopathy and survival.
- Trial name
- PORTAL (NCT07422701)
- Where
- 7 sites in China
- Volunteers
- 2,522 people
- Sponsor
- Peking University First Hospital
Kidney Replacement Disorder
Anticoagulation and Activation - Comparison in Continuous Renal Replacement Therapy
Actual clinical practice predominantly makes use of heparin (systemically) or citrate regionally as anticoagulation in the extracorporeal circulation for renal replacement therapy.
- Trial name
- NCT01276392
- Where
- Germany
- Sponsor
- Klinik für Anästhesiologie
Apical Thrombus Formation, Acute Myocardial Infarction
Implication of Left veNtricle Vortex Flow Guided aNticOagulation Therapy for preVenting Apical Thrombus Formation In Patients With Acute myOcardial infarctioN: Multicenter Prospective Randomized Clinical Trial; INNOVATION Study
Implication of left veNtricle vortex flow guided aNticOagulation therapy for preVenting Apical Thrombus formation In patients with acute myOcardial infarctioN: Multicenter Prospective Randomized Clinical Trial; INNOVATION study
- Trial name
- NCT01869998
- Where
- South Korea
- Volunteers
- 111 people
- Sponsor
- Yonsei University
COVID-19 Pneumonia, Thrombosis
Practice Variation on Antithrombotics in COVID-19
Evidence suggests coronavirus disease 2019 (COVID-19) is associated with an increased incidence of thromboembolic manifestations.
- Conditions
- COVID-19 Pneumonia, Thrombosis, COVID-19 Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS) Pneumonia
- Trial name
- NCT04998799
- Testing
- Current clinical practices of participating physicians
- Where
- India
- Volunteers
- 435 people
- Sponsor
- NMC Specialty Hospital
Immune Thrombocytopenia, Treatment
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
This randomized, open-label study aim to compare the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) with rituximab in ITP patients.This study will be conducted in ITP patients who had not responded to or had…
- Trial name
- NCT07297563
- Testing
- Rituximab, Daratumumab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Gastro Esophageal Reflux
Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)
This will be a randomized clinical trial examining the efficacy and safety of ARAT (intervention group) in patients with chronic GERD symptoms (typical symptoms of GERD, i.e.
- Trial name
- AREA21 (NCT05570448)
- Testing
- ARAT
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Midwest Veterans' Biomedical Research Foundation
Continuous Renal Replacement Therapy, Hyperlactatemia
RCA for CRRT in Hyperlactatemia Patient With Increased Bleeding Risk
The purpose of this single center, randomized, control, open-labeled study is to evaluate the effect and safety of RCA versus no anticoagulation for CRRT in hyperlactatemia patients with increased bleeding risk.
- Conditions
- Continuous Renal Replacement Therapy, Hyperlactatemia, Bleeding
- Trial name
- NCT04315623
- Testing
- Regional citrate anticoagulation CRRT, No-anticoagulation CRRT
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Air Force Military Medical University, China
Oral Anticoagulation
User Performance Evaluation of the INRatio® Prothrombin Time (PT) Monitoring System With a New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity
This multi-center study is designed to evaluate the ability of intended lay users (patients on oral anticoagulation therapy, OAT, or their caregivers) to 1) operate the INRatio Prothrombin Time (PT) Monitoring System utilizing…
- Trial name
- ECLIPSE-02 (NCT01036646)
- Where
- 4 sites in United States
- Volunteers
- 183 people
- Sponsor
- Abbott RDx Cardiometabolic
Atrial Fibrillation, Atrial Flutter
Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation
The purpose of this research study is to test an experimental drug ATI-5923 vs Coumadin. The study is intended to demonstrate ATI-5923 is superior to Coumadin for keeping INR values in the desired therapeutic range.
- Conditions
- Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction
- Trial name
- EmbraceAC (NCT00691470)
- Testing
- ATI-5923, Coumadin (warfarin)
- Where
- 41 sites in United States
- Volunteers
- 600 people
- Sponsor
- ARYx Therapeutics
Pulmonary Embolism
Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. "PADIS-PE" Study.
Rational: After 3 or 6 months of oral anticoagulation for an episode of acute venous thromboembolism (VTE), the risk of recurrent VTE is high (10 to 15% per year) in comparison with a low risk of recurrence if VTE was provoked by…
- Trial name
- PADIS EP (NCT00740883)
- Testing
- warfarin
- Where
- France
- Volunteers
- 374 people
- Sponsor
- University Hospital, Brest
Immune Thrombocytopenia, Treatment
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one…
- Trial name
- NCT06168851
- Testing
- Anti-CD38 antibody Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Stroke, Ischemic
Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial
The overall aim of this research is to improve secondary stroke prevention for older patients with stroke. In current practice, patients with stroke are often prescribed antiplatelet therapy with either aspirin or clopidogrel to…
- Trial name
- STROKE75+ (NCT07454707)
- Testing
- Edoxaban 15 mg, Aspirin or clopidogrel
- Where
- Canada
- Volunteers
- 1,204 people
- Sponsor
- Sunnybrook Health Sciences Centre
Immune Thrombocytopenia, Treatment
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of elderly patients with primary immune thrombocytopenia in patients who have failed multiple treatment.
- Trial name
- NCT07063199
- Testing
- Daratumumab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China